In last trading session, ImmunityBio Inc (NASDAQ:IBRX) saw 12.7 million shares changing hands with its beta currently measuring 1.01. Company’s recent per share price level of $8.54 trading at $0.55 or 6.88% at ring of the bell on the day assigns it a market valuation of $5.76B. That closing price of IBRX’s stock is at a discount of -23.3% from its 52-week high price of $10.53 and is indicating a premium of 85.36% from its 52-week low price of $1.25. Taking a look at company’s average trading volume volume of 6.61 million if we extend that period to 3-months.
ImmunityBio Inc (NASDAQ:IBRX) trade information
Upright in the green during last session for gaining 6.88%, in the last five days IBRX remained trading in the green while hitting it’s week-highest on Monday, 04/29/24 when the stock touched $8.54 price level, adding 18.9% to its value on the day. ImmunityBio Inc’s shares saw a change of 70.12% in year-to-date performance and have moved 77.18% in past 5-day. ImmunityBio Inc (NASDAQ:IBRX) showed a performance of 62.05% in past 30-days.
ImmunityBio Inc (IBRX) estimates and forecasts
Statistics highlight that ImmunityBio Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 177.27% of value to its shares in past 6 months, showing an annual growth rate of 23.23% while that of industry is 12.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 40.70% in the current quarter and calculating 46.90% increase in the next quarter. This year revenue growth is estimated to rise 11,403.20% from the last financial year’s standing.
1 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $20k for the same. And 1 analysts are in estimates of company making revenue of $2.52 million in the next quarter that will end on Jun 2024. Company posted $360k and $41k of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -94.40% while estimating it to be 6,046.30% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.17% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 35.22% while estimates for its earnings growth in next 5 years are of -1.70%.
IBRX Dividends
ImmunityBio Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
